USA flag logo/image

An Official Website of the United States Government

Singlet Oxygen-Mediated Protein Proximity Assay

Award Information

Agency:
Department of Health and Human Services 		Branch:
N/A 		Award ID:
88949 		Program Year/Program:
2008 / SBIR
Agency Tracking Number:
CA134465 		Solicitation Year:
N/A 		Solicitation Topic Code:
N/A 		Solicitation Number:
N/A
Small Business Information
PERSCITUS BIOSCIENCES, LLC
PERSCITUS BIOSCIENCES, LLC 3587 ANDERSON ST, STE 104 MADISON, WI 53704
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 1
Fiscal Year: 2008
Title: Singlet Oxygen-Mediated Protein Proximity Assay
Agency: HHS
Contract: 1R43CA134465-01
Award Amount: $110,000.00
 

Abstract:

DESCRIPTION (provided by applicant): Perscitus Biosciences, LLC, is developing a novel protein proximity assay with broad applications to the pharmaceutical and biomedical community. Currently, there are no satisfactory approaches for examining large prote in complexes in an intact cell and identifying associated proteins that may be important in discerning function. Researchers determine from microarray and other studies that a protein may be implicated in a disease process, but are unable to determine what the function of that protein is within the cell. The protein proximity technology being developed by Perscitus allows for the selective tagging of proteins within a limited radius of the protein of interest. The approach utilizes an active oxygen species, singlet oxygen, created photochemically, that is capable of only limited diffusion from its site of creation. This diffusion distance closely approximates the size of a multimeric protein complex. Singlet oxygen reacts with neighboring proteins, creating a carbonyl group that can be utilized for protein detection, identification and purification. The approach is tunable and precisely initiated at the time of illumination. We are proposing a focused investigation of this protein proximity assay to demonstra te proof of concept that can be used in marketing this approach to pharmaceutical companies. We will initially examine the protein MDM2 because of its broad importance to cancer biology, and the existence of a number of known binding partners that will ser ve as positive controls in our proof of concept studies. The simplicity and scalability of this approach should make for a powerful proteomic method that will have broad applicability to biomedical and pharmaceutical investigators.

Principal Investigator:

Business Contact:


scthomas@tds.net
Small Business Information at Submission:

PERSCITUS BIOSCIENCES, LLC
PERSCITUS BIOSCIENCES, LLC 3587 ANDERSON ST, STE 104 MADISON, WI 53704

EIN/Tax ID: 171101785
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No